Effects of Intrabone Marrow-bone Marrow Transplantation Plus Adult Thymus Transplantation on Survival of Mice Bearing Leukemia

Overview

Journal Stem Cells Dev

Date 2011 Aug 25

PMID 21861761

Citations 6

Authors

Yuming Zhang

Naoki Hosaka

Yunze Cui

Ming Shi

Ming Li

Qing Li

Susumu Ikehara

Affiliations

Soon will be listed here.

Abstract

We recently found that allogeneic intrabone marrow-bone marrow transplantation (IBM-BMT) plus adult thymus transplantation (ATT) from the same donor is effective in mice bearing solid tumors. In the current study, we examined the effects of this strategy on the survival of mice with leukemia. One week after intravenous injection of 1×10(6) leukemic cells (EL-4, H-2(b)) into 8-week-old B6 (H-2(b)) mice, the mice were 8 Gy irradiated and transplanted with 1×10(7) bone marrow cells (BMCs) from 8-week-old BALB/c mice (H-2(d)) by IBM-BMT with or without donor lymphocyte infusion (DLI) or ATT. All the mice without treatment died within 70 days after injection of EL-4. About 40% of those treated with IBM-BMT alone died within 100 days due to tumor relapse. In contrast, those treated with IBM-BMT+DLI or ATT showed the longest survival rate without relapse of leukemia. In addition, the former showed less graft versus host disease (GVHD) than the latter. The mice treated with IBM-BMT+ATT also showed an intermediate percentage of effector memory (EM) and central memory (CM) cells between those treated with BMT alone and those treated with IBM-BMT+DLI. The numbers and functions of T cells increased in those treated with IBM-BMT+ATT with interleukin-2 and interferon-γ production. These results suggest that IBM-BMT+ATT is effective in the treatment of leukemia with strong graft versus leukemia without increased risk of GVHD.

Citing Articles

Thymus transplantation as immunotherapy for the enhancement and/or correction of T cell function.

Hosaka N Med Mol Morphol. 2024; 57(3):155-160.

PMID: 38935299 DOI: 10.1007/s00795-024-00394-z.

Primary and secondary defects of the thymus.

Dinges S, Amini K, Notarangelo L, Delmonte O Immunol Rev. 2024; 322(1):178-211.

PMID: 38228406 PMC: 10950553. DOI: 10.1111/imr.13306.

Induction of γδT cells from HSC-enriched BMCs co-cultured with iPSC-derived thymic epithelial cells.

Hosaka N, Kanda S, Shimono T, Nishiyama T J Cell Mol Med. 2021; 25(22):10604-10613.

PMID: 34687276 PMC: 8581322. DOI: 10.1111/jcmm.16993.

Role of Regulatory T Cells in Tumor-Bearing Mice Treated with Allo-Hematopoietic Stem Cell Transplantation Plus Thymus Transplantation.

Hosaka N J Immunol Res. 2018; 2018:7271097.

PMID: 30057919 PMC: 6051097. DOI: 10.1155/2018/7271097.

Intractable diseases treated with intra-bone marrow-bone marrow transplantation.

Li M, Guo K, Ikehara S Front Cell Dev Biol. 2014; 2:48.

PMID: 25364755 PMC: 4206987. DOI: 10.3389/fcell.2014.00048.

References

Markert M, Hicks C, Bartlett J, Harmon J, Hale L, Greenberg M . Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection. AIDS Res Hum Retroviruses. 2000; 16(5):403-13. DOI: 10.1089/088922200309061. View

Wingard J, Piantadosi S, Vogelsang G, Farmer E, Jabs D, Levin L . Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood. 1989; 74(4):1428-35. View

WEISS L, Lubin I, Factorowich I, Lapidot Z, Reich S, Reisner Y . Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2. J Immunol. 1994; 153(6):2562-7. View

Watson J . Problems of infection after bone marrow transplantation. J Clin Pathol. 1983; 36(6):683-92. PMC: 498351. DOI: 10.1136/jcp.36.6.683. View

Blander J, SantAngelo D, Metz D, Kim S, Flavell R, Bottomly K . A pool of central memory-like CD4 T cells contains effector memory precursors. J Immunol. 2003; 170(6):2940-8. DOI: 10.4049/jimmunol.170.6.2940. View

Russell N, Byrne J, Faulkner R, Gilyead M, Das-Gupta E, Haynes A . Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant. 2005; 36(5):437-41. DOI: 10.1038/sj.bmt.1705074. View

Deol A, Lum L . Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat Rev. 2010; 36(7):528-38. PMC: 2921454. DOI: 10.1016/j.ctrv.2010.03.004. View

Ikehara S . A novel method of bone marrow transplantation (BMT) for intractable autoimmune diseases. J Autoimmun. 2008; 30(3):108-15. DOI: 10.1016/j.jaut.2007.12.011. View

Markert M, Boeck A, Hale L, Kloster A, McLaughlin T, Batchvarova M . Transplantation of thymus tissue in complete DiGeorge syndrome. N Engl J Med. 1999; 341(16):1180-9. DOI: 10.1056/NEJM199910143411603. View

10.

Mehr R, Perelson A, Fridkis-Hareli M, Globerson A . Regulatory feedback pathways in the thymus. Immunol Today. 1998; 18(12):581-5. DOI: 10.1016/s0167-5699(97)01150-x. View

11.

Kushida T, Inaba M, Hisha H, Ichioka N, Esumi T, Ogawa R . Intra-bone marrow injection of allogeneic bone marrow cells: a powerful new strategy for treatment of intractable autoimmune diseases in MRL/lpr mice. Blood. 2001; 97(10):3292-9. DOI: 10.1182/blood.v97.10.3292. View

12.

Zhang Y, Joe G, Hexner E, Zhu J, Emerson S . Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease. J Immunol. 2005; 174(5):3051-8. DOI: 10.4049/jimmunol.174.5.3051. View

13.

Klimpel G, ANNABLE C, Cleveland M, Jerrells T, Patterson J . Immunosuppression and lymphoid hypoplasia associated with chronic graft versus host disease is dependent upon IFN-gamma production. J Immunol. 1990; 144(1):84-93. View

14.

Edinger M, Hoffmann P, Ermann J, Drago K, Fathman C, Strober S . CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003; 9(9):1144-50. DOI: 10.1038/nm915. View

15.

Hosaka N, Cui W, Zhang Y, Takaki T, Inaba M, Ikehara S . Prolonged survival in mice with advanced tumors treated with syngeneic or allogeneic intra-bone marrow-bone marrow transplantation plus fetal thymus transplantation. Cancer Immunol Immunother. 2010; 59(7):1121-30. PMC: 11030866. DOI: 10.1007/s00262-010-0840-2. View

16.

Hosaka N, Ryu T, Miyake T, Cui W, Nishida T, Takaki T . Treatment of autoimmune diseases in MRL/lpr mice by allogenic bone marrow transplantation plus adult thymus transplantation. Clin Exp Immunol. 2007; 147(3):555-63. PMC: 1810495. DOI: 10.1111/j.1365-2249.2006.03310.x. View

17.

Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z . Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev. 2006; 212:8-27. DOI: 10.1111/j.0105-2896.2006.00427.x. View

18.

Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A . Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999; 401(6754):708-12. DOI: 10.1038/44385. View

19.

Cui W, Hosaka N, Miyake T, Wang X, Guo K, Cui Y . Analysis of tolerance induction using triple chimeric mice: major histocompatibility complex-disparate thymus, hemopoietic cells, and microenvironment. Transplantation. 2008; 85(8):1151-8. DOI: 10.1097/TP.0b013e31816a8f1f. View

20.

Lai L, Jin J . Generation of thymic epithelial cell progenitors by mouse embryonic stem cells. Stem Cells. 2009; 27(12):3012-20. DOI: 10.1002/stem.238. View